BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17325912)

  • 1. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
    Yamagata M; Murohisa T; Tsuchida K; Okamoto Y; Tsunoda S; Nakamura M; Kusano K; Majima Y; Kuniyoshi T; Iijima M; Sugaya H; Hiraishi H
    Leuk Lymphoma; 2007 Feb; 48(2):431-3. PubMed ID: 17325912
    [No Abstract]   [Full Text] [Related]  

  • 2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 4. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP plus rituximab--balancing facts and opinion.
    Cheson BD
    N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
    Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
    Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
    Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
    Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
    Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
    Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
    [No Abstract]   [Full Text] [Related]  

  • 11. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
    Dunleavy K; Davis RE; Landgren O; Staudt LM; Wilson WH
    Blood; 2007 Jan; 109(2):843-4; discussion 844-5. PubMed ID: 17210865
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
    Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
    Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
    Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
    Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
    Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
    Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
    Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
    Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
    Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.